Gerald Gartlehner, Barbara Nussbaumer, Bradley N Gaynes, Catherine A Forneris, Laura C Morgan, Angela Kaminski-Hartenthaler, Amy Greenblatt, Jörg Wipplinger, Linda J Lux, Jeffrey H Sonis, Julia Hofmann, Megan G Van Noord, Dietmar Winkler
BACKGROUND: Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This review - one of four reviews on efficacy and safety of interventions to prevent SAD - focuses on second-generation antidepressants (SGAs). OBJECTIVES: To assess the efficacy and safety of second-generation antidepressants (in comparison with other SGAs, placebo, light therapy, melatonin or agomelatine, psychological therapies or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD...
November 8, 2015: Cochrane Database of Systematic Reviews